Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: Non-small cell lung cancer is mostly recognized among other types of lung cancer with a poor prognosis by cause of chemotherapeutic resistance and increased metastasis. Luteolin has been found to decrease cell metastasis. However, its underlying mechanisms remain unresolved. The objective of this study was to examine the effect (and its mechanism) of luteolin on the migration and invasion of human non-small cell lung cancer A549 cells. MATERIALS/METHODS: Cell viability was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Wound healing and transwell assays were evaluated to assess migration and invasion, respectively. Western blot analysis and immunofluorescence were further performed to investigate the role of luteolin and its mechanisms of action. RESULTS: Administration with up to 40 μM luteolin showed no cytotoxic activity on lung cancer A549 cells or non-cancer MRC-5 cells. Additionally, luteolin at 20-40 μM significantly suppressed A549 cells’ migration, invasion, and the formation of filopodia in a concentration-dependent manner at 24 h. This is similar with western blot analysis, which revealed diminished the phosphorylated focal adhesion kinase (pFAK), phosphorylated non-receptor tyrosine kinase (pSrc), Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), and Ras homolog gene family member A (RhoA) expression levels. CONCLUSIONS: Overall, our data indicate that luteolin plays a role in controlling lung cancer cells’ migration and invasion via Src/FAK and its downstream Rac1, Cdc42, and RhoA pathways. Luteolin might be considered a promising candidate for suppressing invasion and metastasis of lung cancer cells.
Abstract
BACKGROUND/OBJECTIVES: Non-small cell lung cancer is mostly recognized among other types of lung cancer with a poor prognosis by cause of chemotherapeutic resistance and increased metastasis. Luteolin has been found to decrease cell metastasis. However, its underlying mechanisms remain unresolved. The objective of this study was to examine the effect (and its mechanism) of luteolin on the migration and invasion of human non-small cell lung cancer A549 cells. MATERIALS/METHODS: Cell viability was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Wound healing and transwell assays were evaluated to assess migration and invasion, respectively. Western blot analysis and immunofluorescence were further performed to investigate the role of luteolin and its mechanisms of action. RESULTS: Administration with up to 40 μM luteolin showed no cytotoxic activity on lung cancer A549 cells or non-cancer MRC-5 cells. Additionally, luteolin at 20-40 μM significantly suppressed A549 cells’ migration, invasion, and the formation of filopodia in a concentration-dependent manner at 24 h. This is similar with western blot analysis, which revealed diminished the phosphorylated focal adhesion kinase (pFAK), phosphorylated non-receptor tyrosine kinase (pSrc), Ras-related C3 botulinum toxin substrate 1 (Rac1), cell division control protein 42 (Cdc42), and Ras homolog gene family member A (RhoA) expression levels. CONCLUSIONS: Overall, our data indicate that luteolin plays a role in controlling lung cancer cells’ migration and invasion via Src/FAK and its downstream Rac1, Cdc42, and RhoA pathways. Luteolin might be considered a promising candidate for suppressing invasion and metastasis of lung cancer cells.
참고문헌 (46)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Sher T, "Small cell lung cancer", Mayo Clin Proc, 83, pp.355~367 (2008)
- Artal Cortés Á, "Adjuvant chemotherapy in non-small cell lung cancer : state-of-the-art", Transl Lung Cancer Res, 4, pp.191~197 (2015)
- Hall A, "Rho GTPases and the actin cytoskeleton", Science, 279, pp.509~514 (1998)
- Ridley AJ, "Rho GTPases and cell migration", J Cell Sci, 114, pp.2713~2722 (2001)
- Iden S, "Crosstalk between small GTPases and polarity proteins in cell polarization", Nat Rev Mol Cell Biol, 9, pp.846~859 (2008)
- Tomar A, "Focal adhesion kinase : switching between GAPs and GEFs in the regulation of cell motility", Curr Opin Cell Biol, 21, pp.676~683 (2009)
- Lee BY, "FAK signaling in human cancer as a target for therapeutics", Pharmacol Ther, 146, pp.132~149 (2015)
- Yeatman TJ, "A renaissance for SRC", Nat Rev Cancer, 4, pp.470~480 (2004)
- Zhang S, "Targeting Src family kinases in anti-cancer therapies : turning promise into triumph", Trends Pharmacol Sci, 33, pp.122~128 (2012)
- Park GB, "Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk", Src pathway, 2018, pp.17, 3563~3574
- Mitra SK, "Integrin-regulated FAK-Src signaling in normal and cancer cells", Curr Opin Cell Biol, 18, pp.516~523 (2006)
- Prateep A, "Avicequinone B sensitizes anoikis in human lung cancer cells", J Biomed Sci, 25, pp.32~ (2018)
- Miean KH, "Flavonoid(myricetin, quercetin, kaempferol, luteolin, and apigenin)content of edible tropical plants", J Agric Food Chem, 49, pp.3106~3112 (2001)
- Imran M, "Luteolin, a flavonoid, as an anticancer agent : a review", Biomed Pharmacother, 112, pp.108612~ (2019)
- López-Lázaro M, "Distribution and biological activities of the flavonoid luteolin", Mini Rev Med Chem, 9, pp.31~59 (2009)
- Xu T, "Targeting cell signaling and apoptotic pathways by luteolin : cardioprotective role in rat cardiomyocytes following ischemia", reperfusion, 2012, pp.4, 2008~2019
- Birt DF, "Dietary agents in cancer prevention : flavonoids and isoflavonoids", Pharmacol Ther, 90, pp.157~177 (2001)
- Martin KR, "Targeting apoptosis with dietary bioactive agents", Exp Biol Med(Maywood), 231, pp.117~129 (2006)
- Rauf A, "Resveratrol as an anti-cancer agent : a review", Crit Rev Food Sci Nutr, 58, pp.1428~1447 (2018)
- Chen KC, "Luteolin attenuates TGF-β1-induced epithelial-mesenchymal transition of lung cancer cells by interfering in the PI3K", Akt-NF-κB-Snail pathway, 2013, pp.93, 924~933
- Ma L, "Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis", Mol Med Rep, 12, pp.4196~4202 (2015)
- Wang Q, "Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p-IGF-1R", PI3K, mTOR signaling pathway, pp.Oncol Lett, 2017[DOI]
- Sukketsiri W, "Anti-apoptotic effects of phyllanthin against alcohol induced liver cell death", Trop J Pharm Res, 5, pp.981~988 (2016)
- Singkhorn S, "Induction of keratinocyte migration by ECa 233 is mediated through FAK", Akt, ERK, and p38 MAPK signaling, 2018, pp.32, 1397~1403
- Sit ST, "Rho GTPases and their role in organizing the actin cytoskeleton", J Cell Sci, 124, pp.679~683 (2011)
- Lin Y, "Luteolin, a flavonoid with potential for cancer prevention and therapy", Curr Cancer Drug Targets, 8, pp.634~646 (2008)
- Chen P, "Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450", Oncotarget, 8, pp.27471~27480 (2017)
- Cherng JM, "Chemopreventive effects of minor dietary constituents in common foods on human cancer cells", Biosci Biotechnol Biochem, 71, pp.1500~1504 (2007)
- Pu Y, "Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs", J Cancer, 9, pp.3669~3675 (2018)
- Molina JR, "Non-small cell lung cancer : epidemiology, risk factors, treatment, and survivorship", Mayo Clin Proc, 83, pp.584~594 (2008)
- Cook MT, "Mechanism of metastasis suppression by luteolin in breast cancer", Breast Cancer(Dove Med Press), 10, pp.89~100 (2018)
- Carelli S, "Up-regulation of focal adhesion kinase in non-small cell lung cancer", Lung Cancer, 53, pp.263~271 (2006)
- Ji HF, "Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer", J Cancer Res Clin Oncol, 139, pp.429~435 (2013)
- Mazurenko NN, "Expression of pp60c-src in human small cell and non-small cell lung carcinomas", Eur J Cancer, 28, pp.372~377 (1992)
- Bolós V, "The dual kinase complex FAK-Src as a promising therapeutic target in cancer", Onco Targets Ther, 3, pp.83~97 (2010)
- Carragher NO, "Focal adhesion and actin dynamics : a place where kinases and proteases meet to promote invasion", Trends Cell Biol, 14, pp.241~249 (2004)
- Gu MM, "p53-inducible gene 3 promotes cell migration and invasion by activating the FAK", Src pathway in lung adenocarcinoma, 2018, pp.109, 3783~3793
- Schaller MD, "Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src", Mol Cell Biol, 14, pp.1680~1688 (1994)
- Chen M, "Integrin-induced tyrosine phosphorylation of protein-tyrosine phosphatase-alpha is required for cytoskeletal reorganization and cell migration", J Biol Chem, 281, pp.11972~11980 (2006)
- Hsia DA, "Differential regulation of cell motility and invasion by FAK", J Cell Biol, 160, pp.753~767 (2003)
- Chikara S, "Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines", BMC Complement Altern Med, 17, pp.30~ (2017)
- Sandilands E, "Endosomal trafficking of Src tyrosine kinase", Trends Cell Biol, 18, pp.322~329 (2008)
- Gardel ML, "Mechanical integration of actin and adhesion dynamics in cell migration", Annu Rev Cell Dev Biol, 26, pp.315~333 (2010)
- Kim LC, "Src kinases as therapeutic targets for cancer", Nat Rev Clin Oncol, 6, pp.587~595 (2009)
- Summy JM, "Src family kinases in tumor progression and metastasis", Cancer Metastasis Rev, 22, pp.337~358 (2003)